Chugai Pharmaceutical Co., Ltd. CHGCF
OTC PK
| 06/30/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | 7.20B | 6.99B | 6.85B | |
| Total Other Revenue | -- | 1.20B | 1.15B | 1.15B | |
| Total Revenue | -- | 8.41B | 8.14B | 8.01B | |
| Cost of Revenue | -- | 2.43B | 2.48B | 2.37B | |
| Gross Profit | -- | 5.97B | 5.66B | 5.63B | |
| SG&A Expenses | -- | 777.89M | 750.86M | 748.65M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -59.93M | -64.37M | -75.18M | |
| Total Operating Expenses | -- | 4.41B | 4.43B | 4.27B | |
| Operating Income | -- | 4.00B | 3.71B | 3.73B | |
| Income Before Tax | -- | 3.99B | 3.71B | 3.72B | |
| Income Tax Expenses | -- | 1.10B | 1.05B | 1.08B | |
| Earnings from Continuing Operations | -- | 2.90K | 2.67K | 2.65K | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | 2.90B | 2.67B | 2.65B | |
| EBIT | -- | 4.00B | 3.71B | 3.73B | |
| EBITDA | -- | 4.21B | 3.92B | 3.94B | |
| EPS Basic | -- | 1.76 | 1.62 | 1.61 | |
| Normalized Basic EPS | -- | 0.78 | 0.67 | 0.67 | |
| EPS Diluted | -- | 1.76 | 1.62 | 1.61 | |
| Normalized Diluted EPS | -- | 0.78 | 0.67 | 0.67 | |
| Average Basic Shares Outstanding | -- | 6.58B | 6.58B | 6.58B | |
| Average Diluted Shares Outstanding | -- | 6.58B | 6.58B | 6.58B | |
| Dividend Per Share | -- | 0.81 | 0.72 | 0.72 | |
| Payout Ratio | -- | 69.38% | 75.52% | 40.48% | |